JP2013528591A5 - - Google Patents

Download PDF

Info

Publication number
JP2013528591A5
JP2013528591A5 JP2013509260A JP2013509260A JP2013528591A5 JP 2013528591 A5 JP2013528591 A5 JP 2013528591A5 JP 2013509260 A JP2013509260 A JP 2013509260A JP 2013509260 A JP2013509260 A JP 2013509260A JP 2013528591 A5 JP2013528591 A5 JP 2013528591A5
Authority
JP
Japan
Prior art keywords
methyl
alkyl
oxo
indazole
carboxamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013509260A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013528591A (ja
JP5864546B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/035340 external-priority patent/WO2011140325A1/en
Publication of JP2013528591A publication Critical patent/JP2013528591A/ja
Publication of JP2013528591A5 publication Critical patent/JP2013528591A5/ja
Application granted granted Critical
Publication of JP5864546B2 publication Critical patent/JP5864546B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013509260A 2010-05-07 2011-05-05 インダゾール Expired - Fee Related JP5864546B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33231210P 2010-05-07 2010-05-07
US61/332,312 2010-05-07
PCT/US2011/035340 WO2011140325A1 (en) 2010-05-07 2011-05-05 Indazoles

Publications (3)

Publication Number Publication Date
JP2013528591A JP2013528591A (ja) 2013-07-11
JP2013528591A5 true JP2013528591A5 (enExample) 2015-08-06
JP5864546B2 JP5864546B2 (ja) 2016-02-17

Family

ID=44904073

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013509260A Expired - Fee Related JP5864546B2 (ja) 2010-05-07 2011-05-05 インダゾール

Country Status (5)

Country Link
US (2) US8846935B2 (enExample)
EP (1) EP2566328B1 (enExample)
JP (1) JP5864546B2 (enExample)
ES (1) ES2534804T3 (enExample)
WO (1) WO2011140325A1 (enExample)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012012966A (es) * 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
US20130102477A1 (en) 2010-06-23 2013-04-25 Ryan D. Morin Biomarkers for non-hodgkin lymphomas and uses thereof
AU2011298987B2 (en) 2010-09-10 2017-09-28 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
US9175331B2 (en) 2010-09-10 2015-11-03 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
JP5908493B2 (ja) * 2010-12-01 2016-04-26 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC インドール
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
JO3438B1 (ar) * 2011-04-13 2019-10-20 Epizyme Inc مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
TW201733984A (zh) 2011-04-13 2017-10-01 雅酶股份有限公司 經取代之苯化合物
AU2013203641B2 (en) * 2011-04-13 2014-08-21 Epizyme, Inc. Aryl-or heteroaryl-substituted benzene compounds
EP2570125A1 (en) 2011-09-16 2013-03-20 Almirall, S.A. Ep1 receptor ligands
JP2014534178A (ja) * 2011-09-30 2014-12-18 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーGlaxoSmithKline LLC 癌の処置方法
CA2854447A1 (en) 2011-11-04 2013-05-10 Glaxosmithkline Intellectual Property (No.2) Limited Method of treatment
EP2780014A4 (en) * 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
EP2780013A4 (en) * 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
NZ628762A (en) 2012-02-10 2016-07-29 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
AU2013232229B2 (en) 2012-03-12 2017-11-23 Epizyme, Inc. Inhibitors of human EZH2, and methods of use thereof
LT2836491T (lt) 2012-04-13 2017-03-27 Epizyme, Inc. Žmogaus histono metiltransferazės ezh2 slopiklio druskos forma
US9562041B2 (en) 2012-05-16 2017-02-07 Glaxosmithkline Llc Enhancer of zeste homolog 2 inhibitors
WO2013188848A2 (en) * 2012-06-15 2013-12-19 The Regents Of The University Of California Antiviral compounds and methods of use
JP6254169B2 (ja) * 2012-09-28 2017-12-27 ファイザー・インク ベンズアミドおよびヘテロベンズアミド化合物
RU2018145311A (ru) 2012-10-15 2019-02-18 Эпизайм, Инк. Способы лечения рака
JP6461802B2 (ja) 2012-10-15 2019-01-30 エピザイム,インコーポレイティド 置換ベンゼン化合物
SMT201800070T1 (it) 2012-12-19 2018-03-08 Celgene Quanticel Res Inc Inibiorti di istone demetilasi
WO2014100080A1 (en) * 2012-12-19 2014-06-26 Glaxosmithkline Llc Combination
EP2935264B1 (en) 2012-12-21 2017-10-18 Epizyme, Inc. 1,4-pyridone bicyclic heteroaryl compounds
UA111305C2 (uk) 2012-12-21 2016-04-11 Пфайзер Інк. Конденсовані лактами арилу та гетероарилу
KR20150127216A (ko) 2013-03-14 2015-11-16 제넨테크, 인크. 암의 치료 및 암 약물 내성의 예방 방법
EP2970305B1 (en) 2013-03-15 2017-02-22 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
HK1214815A1 (zh) 2013-04-30 2016-08-05 Glaxosmithkline Intellectual Property (No. 2) Limited Zeste增强子同源物2的抑制剂
CN105473580A (zh) 2013-07-10 2016-04-06 葛兰素史密斯克莱知识产权(第2号)有限公司 Zeste同源物增强子2抑制剂
EP3033334A1 (en) 2013-08-15 2016-06-22 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
HUE063984T2 (hu) 2013-10-16 2024-02-28 Epizyme Inc Hidroklorid só forma az EZH2 gátlásához
US9822103B2 (en) 2013-11-22 2017-11-21 Bristol-Myers Squibb Company Inhibitors of lysine methyl transferase
US20160361309A1 (en) 2014-02-26 2016-12-15 Glaxosmithkline Intellectual Property (No.2) Limited Methods of treating cancer patients responding to ezh2 inhibitor gsk126
CN105017221B (zh) * 2014-04-30 2019-05-28 中国医学科学院药物研究所 苯并咪唑衍生物及其制法和药物组合物与用途
CN107207464B (zh) 2014-06-17 2019-10-22 辉瑞大药厂 被取代的二氢异喹啉酮化合物
ES2751464T3 (es) 2014-09-17 2020-03-31 Celgene Quanticel Res Inc Inhibidores de histona desmetilasa
EP3885343A1 (en) * 2014-11-06 2021-09-29 Dana-Farber Cancer Institute, Inc. Indole compounds as ezh2 inhibitors and uses thereof
TW201636344A (zh) 2014-12-05 2016-10-16 美國禮來大藥廠 Ezh2抑制劑
MA41140A (fr) 2014-12-12 2017-10-17 Cancer Research Tech Ltd Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
MA41179A (fr) * 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
WO2016101956A2 (en) 2014-12-23 2016-06-30 University Of Copenhagen Treatment of cancer by inhibiting ezh2 activity
EP3283502A4 (en) 2015-04-07 2019-04-03 The General Hospital Corporation METHOD FOR REACTIVATING GENES ON THE INACTIVE X-CHROMOSOME
CN108025191A (zh) 2015-08-24 2018-05-11 Epizyme股份有限公司 治疗癌症的方法
TW201718598A (zh) 2015-08-27 2017-06-01 美國禮來大藥廠 Ezh2抑制劑
US10577350B2 (en) 2015-08-28 2020-03-03 Constellation Pharmaceuticals, Inc. Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide
US11059817B2 (en) 2015-09-23 2021-07-13 The Regents Of The University Of California Potent antiviral pyrazolopyridine compounds
CN108699046A (zh) * 2015-10-06 2018-10-23 Epizyme股份有限公司 用ezh2抑制剂治疗成神经管细胞瘤的方法
DK3378859T3 (da) 2015-11-19 2020-01-20 Jiangsu Hengrui Medicine Co Benzofuranderivater, fremgangsmåde til fremstilling deraf og anvendelse deraf i medicin
KR102852334B1 (ko) 2016-02-10 2025-09-01 웨이크 포리스트 유니버시티 헬스 사이언시즈 간 섬유화의 모델 시스템 및 그의 제조 및 사용 방법
WO2017157825A1 (en) 2016-03-15 2017-09-21 F. Hoffmann-La Roche Ag Combinations of lsd1 inhibitors for use in the treatment of solid tumors
WO2017192290A1 (en) 2016-05-04 2017-11-09 The Wistar Institute Of Anatomy And Biology Methods of treating cancers overexpressing carm1 with ezh2 inhibitors and platinum-based antineoplastic drugs
CN107573327B (zh) * 2016-07-05 2020-03-31 四川大学 吲唑-甲酰胺-吡啶酮衍生物及其制备方法和用途
MA46199A (fr) * 2016-09-07 2019-07-17 Shanghai Haihe Pharmaceutical Co Ltd Composé cyclique aromatique de pyrido à cinq éléments, son procédé de préparation et son utilisation
WO2018075598A1 (en) 2016-10-19 2018-04-26 Constellation Pharmaceuticals, Inc. Synthesis of inhibitors of ezh2
WO2018086592A1 (zh) * 2016-11-11 2018-05-17 上海海雁医药科技有限公司 4,5,6-三取代吲唑类衍生物、其制法与医药上的用途
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
MX386586B (es) 2017-05-18 2025-03-19 Jiangsu Hengrui Medicine Co Cristal de base libre de derivados benzofurano y método de preparación.
WO2019057946A1 (en) 2017-09-25 2019-03-28 F. Hoffmann-La Roche Ag MULTI-CYCLIC AROMATIC COMPOUNDS AS D-FACTOR INHIBITORS
EP3708567A4 (en) * 2017-11-10 2021-07-07 Jiangsu Hengrui Medicine Co., Ltd. PROCESS FOR THE PREPARATION OF A BENZOFURANE DERIVATIVE
BR112020008325A2 (pt) 2017-11-14 2020-10-20 Pfizer Inc. terapias de combinação com o inibidor de ezh2
CN110016014B (zh) * 2018-01-08 2023-02-17 中国科学院上海药物研究所 Ezh2抑制剂及其制备和抗肿瘤治疗中的应用
WO2019152419A1 (en) 2018-01-31 2019-08-08 Mirati Therapeutics, Inc Prc2 inhibitors
CN110229157B (zh) * 2018-03-06 2022-06-21 上海海和药物研究开发股份有限公司 嘧啶并五元芳香杂环类化合物、其制备方法及用途
CZ308400B6 (cs) * 2018-04-11 2020-07-29 Univerzita Karlova Farmaceutický přípravek pro léčení maligního melanomu
EP3823671B1 (en) 2018-07-09 2024-02-07 Fondation Asile Des Aveugles Inhibition of prc2 subunits to treat eye disorders
CA3106589A1 (en) 2018-07-27 2020-01-30 Suzhou Sinovent Pharma Co., Ltd. Polysubstituted benzene compound and preparation method and use thereof
EP3841062A4 (en) * 2018-08-24 2022-06-01 Shanghai Tetrels Material Technology Co., Ltd. Devices and methods for water-filtration membranes
EP3959214A1 (en) 2019-04-22 2022-03-02 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
CA3142711A1 (en) 2019-06-05 2020-12-10 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
WO2023025856A1 (en) 2021-08-25 2023-03-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of ezh2 inhibitors for the treatment of aortic valve stenosis
CN116768857A (zh) * 2022-03-09 2023-09-19 中国药科大学 Ezh2/hdac双靶点抑制剂及其制备方法和医药用途
WO2023183850A1 (en) 2022-03-23 2023-09-28 Ideaya Biosciences, Inc. Piperazine substituted indazole compounds as inhibitors of parg
US20250270191A1 (en) 2022-06-13 2025-08-28 Treeline Biosciences, Inc. Quinolone bcl6 bifunctional degraders
WO2023244917A1 (en) 2022-06-13 2023-12-21 Treeline Biosciences, Inc. 1,8-naphthyridin-2-one heterobifunctional bcl6 degraders
WO2025064745A1 (en) * 2023-09-20 2025-03-27 Ideaya Biosciences, Inc. Parg inhibitor
CN117362277B (zh) * 2023-10-13 2025-02-11 沈阳药科大学 含咪唑啉酮结构的苯甲酰胺类化合物及其制备方法和应用
WO2025248032A1 (en) 2024-05-31 2025-12-04 Syngenta Crop Protection Ag Pesticidally active indazole compounds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU771928B2 (en) * 1999-05-19 2004-04-08 Pharmacia Corporation Substituted polycyclic aryl and heteroaryl pyridones useful for selective inhibition of the coagulation cascade
TW200303304A (en) * 2002-02-18 2003-09-01 Astrazeneca Ab Chemical compounds
WO2004112719A2 (en) 2003-06-19 2004-12-29 Smithkline Beecham Corporation Chemical compounds
US20090012031A1 (en) * 2007-07-03 2009-01-08 The Regents Of The University Of Michigan EZH2 Cancer Markers
JP5364875B2 (ja) 2007-07-16 2013-12-11 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬としてのインダゾール類、ベンゾイソオキサゾール類およびベンゾイソチアゾール類
JP5216912B2 (ja) * 2008-04-29 2013-06-19 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr1受容体拮抗薬としてのインダゾール化合物
CN102369204A (zh) 2008-09-26 2012-03-07 新加坡科技研究局 3-脱氮瓶菌素衍生物
ES2528269T3 (es) 2010-05-07 2015-02-06 Glaxosmithkline Llc Azaindazoles
MX2012012966A (es) 2010-05-07 2013-01-22 Glaxosmithkline Llc Indoles.
EP3323820B1 (en) 2011-02-28 2023-05-10 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds

Similar Documents

Publication Publication Date Title
JP2013528591A5 (enExample)
JP2013527173A5 (enExample)
JP2013544840A5 (enExample)
JP2013525498A5 (enExample)
CA2798622A1 (en) Indoles
AU2003252011B8 (en) Substituted 2-alkylamine nicotinic amide derivatives and use there of
ES2778700T3 (es) Nuevos derivados de piperidinilo sustituidos con (hetero)arilo, un proceso para su preparación y composiciones farmacéuticas que los contienen
JP6759100B2 (ja) 治療用阻害化合物
AU2006200437B2 (en) Substituted alkylamine derivatives and methods of use
CN100506801C (zh) 糖元合成酶激酶3的抑制剂
EA016028B1 (ru) Конденсированные гетероциклические производные и их применение
JP2010513444A5 (enExample)
MXPA04007970A (es) Compuestos de tiazolil urea para el tratamiento de cancer.
TW200536851A (en) Compounds and methods of use
AU2011272198A1 (en) Novel nicotinamide derivatives or salts thereof
JP2015501784A5 (enExample)
JP2015025014A (ja) キナーゼ阻害剤として有用な2−アミノピリジン誘導体
AU2002248340A1 (en) Substituted alkylamine derivatives and methods of use
KR20080112202A (ko) Pi-3 키나제 억제제 및 그것의 사용 방법
WO2006071940A2 (en) Enzyme modulators and treatments
CN102740698A (zh) 用于激酶调节的化合物和方法及其适应症
KR20150007349A (ko) Nampt 억제제
US20250179013A1 (en) Inhibitors of rna helicase dhx9 and uses thereof
JP2020512401A5 (enExample)
TWI335325B (en) Substituted alkylamine derivatives and methods of use